Bailard, Inc. Cytek Biosciences, Inc. Transaction History

Bailard, Inc.

$4.45 Billion
Q3 2025

A detailed history of Bailard, Inc. transactions in Cytek Biosciences, Inc. stock. As of the latest transaction made, Bailard, Inc. holds 29,300 shares of CTKB stock, worth $161,150. This represents 0.0% of its overall portfolio holdings.

Number of Shares

29,300

Holding current value

$161,150

% of portfolio

0.0%

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2025 Oct 30, 2025	BUY	$3.1 - $4.17 $90,830 - $122,181	29,300 New	29,300 $101,000
Q4 2024 Feb 05, 2025	BUY	$4.7 - $7.4 $88,830 - $139,860	18,900 New	18,900 $122,000

Others Institutions Holding CTKB

# of Institutions

151

Shares Held

72.8M

Call Options Held

Put Options Held

Black Rock Inc. New York, NY

17.1M
Shares

$93.9 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

6.93M
Shares

$38.1 Million
0.0% of portfolio
Hhlr Advisors, Ltd. Grand Cayman, E9

6.66M
Shares

$36.6 Million
0.69% of portfolio
Brown Capital Management LLC Baltimore, MD

4.96M
Shares

$27.3 Million
0.74% of portfolio
State Street Corp Boston, MA

4.08M
Shares

$22.5 Million
0.0% of portfolio

View Full List

About Cytek Biosciences, Inc.

Ticker CTKB
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 134,627,008
Market Cap $740M
Description
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers ...

More about CTKB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bailard, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Bailard, Inc. with notifications on news.

Account